The Benefits of Intensive Versus Standard Blood Pressure Treatment According to Fine Particulate Matter Air Pollution Exposure: A Post Hoc Analysis of SPRINT

根据细颗粒物空气污染暴露情况,强化血压治疗与标准血压治疗的益处:SPRINT 研究的事后分析

阅读:1

Abstract

Fine particulate matter <2.5 µm (PM(2.5)) air pollution is implicated in global mortality, especially from cardiovascular causes. A large body of evidence suggests a link between PM(2.5) and elevation in blood pressure (BP), with the latter implicated as a potential mediator of cardiovascular events. We sought to determine if the outcomes of intensive BP lowering (systolic BP <120 mm Hg) on cardiovascular events are modified by PM(2.5) exposure in the SPRINT (Systolic BP Intervention Trial). We linked annual PM(2.5) exposure estimates derived from an integrated model to subjects participating in SPRINT. We evaluated the effect of intensive BP lowering by PM(2.5) exposure on the primary outcome in SPRINT using cox-proportional hazard models. A total of 9286 participants were linked to PM(2.5) levels (mean age 68±9 years). Intensive BP-lowering decreased risk of the primary outcome more among patients exposed to higher PM(2.5) (P(interaction)=0.047). The estimate for lowering of primary outcome was numerically lower in the highest than in the lower quintiles. The benefits of intensive BP-lowering were larger among patients chronically exposed to PM(2.5) levels above US National Ambient Air Quality Standards of 12 µg/m(3) (hazard ratio, 0.47 [95% CI, 0.29-0.74]) compared with those living in cleaner locations (hazard ratio, 0.81 [95% CI, 0.68-0.97]), P(interaction)=0.037. This exploratory nonprespecified post hoc analysis of SPRINT suggests that the benefits of intensive BP lowering on the primary outcome was greater in patients exposed to higher PM(2.5), suggesting that the magnitude of benefit may depend upon the magnitude of antecedent PM(2.5) exposure.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。